Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem
- PMID: 21102998
- PMCID: PMC2954706
- DOI: 10.1093/sleep/33.11.1562
Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem
Abstract
Objective: to evaluate cyclic alternating pattern (CAP) in a phase advance model of transient insomnia and the effects of gaboxadol and zolpidem.
Design: a randomized, double-blind, cross-over study in which habitual sleep time was advanced by 4 h.
Setting: 6 sleep research laboratories in US PARTICIPANTS: 55 healthy subjects (18-57 y)
Interventions: Gaboxadol 15 mg (GBX), zolpidem 10 mg (ZOL), and placebo (PBO).
Measurements: routine polysomnographic (PSG) measures, CAP, spectral power density, and self-reported sleep measures
Results: The phase advance model of transient insomnia produced significant changes in CAP parameters. Both GBX and ZOL significantly and differentially modified CAP parameters in the direction of more stable sleep. GBX brought the CAP rate in stage 1 sleep and slow wave sleep (SWS) closer to baseline levels but did not significantly change the CAP rate in stage 2. ZOL reduced the CAP rate in stage 2 to near baseline levels, whereas the CAP rate in stage 1 and SWS was reduced substantially below baseline levels. The CAP parameter A1 index (associated with SWS and sleep continuity) showed the highest correlation with self-reported sleep quality, higher than any traditional PSG, spectral, or other self-reported measures.
Conclusion: disruptions in CAP produced by phase advanced sleep were significantly and differentially modulated by gaboxadol and zolpidem. The relative independence of CAP parameters from other electrophysiological measures of sleep, their high sensitivity to sleep disruption, and their strong association with subjective sleep quality suggest that CAP variables may serve as valuable endpoints in future insomnia research.
Keywords: CAP; Gaboxadol; extrasynaptic GABA agonist; phase advance; spectral analysis; transient insomnia; zolpidem.
Figures

Similar articles
-
The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia.Sleep. 2007 May;30(5):593-602. doi: 10.1093/sleep/30.5.593. Sleep. 2007. PMID: 17552374 Clinical Trial.
-
Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial.Sleep Med. 2008 May;9(4):393-402. doi: 10.1016/j.sleep.2007.06.006. Epub 2007 Aug 30. Sleep Med. 2008. PMID: 17765013 Clinical Trial.
-
Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia.Psychopharmacology (Berl). 2007 Nov;195(1):139-46. doi: 10.1007/s00213-007-0866-0. Epub 2007 Jul 27. Psychopharmacology (Berl). 2007. PMID: 17653697 Clinical Trial.
-
Gaboxadol--a new awakening in sleep.Curr Opin Pharmacol. 2006 Feb;6(1):30-6. doi: 10.1016/j.coph.2005.10.004. Epub 2005 Dec 20. Curr Opin Pharmacol. 2006. PMID: 16368265 Review.
-
Zolpidem.2018 Feb 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Feb 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643295 Free Books & Documents. Review.
Cited by
-
Extracting more information from EEG recordings for a better description of sleep.Comput Methods Programs Biomed. 2012 Dec;108(3):961-72. doi: 10.1016/j.cmpb.2012.05.009. Epub 2012 Jul 3. Comput Methods Programs Biomed. 2012. PMID: 22763233 Free PMC article.
-
Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.Sleep. 2014 Oct 1;37(10):1609-19. doi: 10.5665/sleep.4068. Sleep. 2014. PMID: 25197807 Free PMC article. Clinical Trial.
-
Characterization of cyclic alternating pattern during sleep in older men and women using large population studies.Sleep. 2020 Jul 13;43(7):zsaa016. doi: 10.1093/sleep/zsaa016. Sleep. 2020. PMID: 32022886 Free PMC article.
-
Quantitative measurement of sleep quality using cardiopulmonary coupling analysis: a retrospective comparison of individuals with and without primary insomnia.Sleep Breath. 2013 May;17(2):713-21. doi: 10.1007/s11325-012-0747-6. Epub 2012 Jul 26. Sleep Breath. 2013. PMID: 22833347
-
A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults.Hum Psychopharmacol. 2022 Jan;37(1):e2806. doi: 10.1002/hup.2806. Epub 2021 Aug 5. Hum Psychopharmacol. 2022. PMID: 34352138 Free PMC article. Clinical Trial.
References
-
- Terzano MG, Parrino L, Smerieri A, et al. Atlas, rules, and recording techniques for the scoring of cyclic alternating pattern (CAP) in human sleep. Sleep Med. 2001;2:537–53. - PubMed
-
- Ferini-Strambi L, Bianchi A, Zucconi M, Oldani A, Castronovo V, Smirne S. The impact of cyclic alternating pattern on heart rate variability during sleep in healthy young adults. Clin Neurophysiol. 2000;111:99–101. - PubMed
-
- Ferri R, Parrino L, Smerieri A, et al. Cyclic alternating pattern and spectral analysis of heart rate variability during normal sleep. J Sleep Res. 2000;9:13–8. - PubMed
-
- Sforza E, Jouny C, Ibanez V. Cardiac activation during arousal in humans: further evidence for hierarchy in the arousal response. Clin Neurophysiol. 2000;111:1611–9. - PubMed
-
- Terzano MG, Parrino L. Origin and significance of the cyclic alternating pattern (CAP) Sleep Med Rev. 2000;4:101–23. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous